Researchers investigated the therapeutic potential of Ruxolitinib cream in patients with vitiligo, and it looks very promising. Results of a 2-year Phase II study at 26 medical centres in 18 states were published in the Lancet just now.
Ruxolitinib is part of a class of medications called Janus Kinase (JAK) inhibitors. Janus kinases play a significant role in the development of vitiligo, and thus blocking their signaling pathways with the drug can -- hypothetically -- treat vitiligo.
Findings from this study suggest that ruxolitinib cream might be an effective treatment option for patients with vitiligo. Once- and twice-daily application at various doses led to significant repigmentation of vitiligo lesions in the face and upper body. The highest response rate was seen with a higher dose, between 24 and 52 weeks of treatment. Some patients got 90% of the color back on the face, yet the majority reported over 50% improvement. The most common treatment-related adverse event was application site pruritus. Approximately 10% of the patients treated with the ruxolitinib cream experienced acne.
Full approval of the drug is still a ways off, but the outlook is promising. The last Phase 3 clinical trilas for Ruxolitinib cream for vitiligo is scheduled to start at the end of this year.
Update May 17, 2021: Positive Outlook For Vitiligo With Topical Ruxolitinib
- Does halo nevi affect vitiligo development?
Halo nevi — nevi with an depigmented circle around it, usually on the trunk — are about 10x more common in vitiligo patients than in the general population, especially in childr...
- Pyrostegia venusta as a folk medicine for vitiligo?
Pyrostegia venusta is a neotropical evergreen vine widely spread in Brazil throughout fields, at the coast, edge of the woods and along roadsides (see photo below). Popularly kn...
- How to get insurance coverage for vitiligo treatments?
Most of health insurance companies will initially reject claims for vitiligo doctor visits or phototherapy treatments but with enough efforts you can have a substantial part of ...
Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.Copyright (C) Bodolóczki Júlia
By taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.